Nuvectis Pharma, Inc. (NVCT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Nuvectis Pharma, Inc. (NVCT) closed at USD 18.00 on 2026-10-14, a change of +179.9 % over the past year, with a market capitalization of USD 617.95M.

Nuvectis Pharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Nuvectis Pharma, Inc. key figures

Previous close

USD 18.00 (2026-10-14)

1-year change

+179.9 %

Market cap

USD 617.95M

Enterprise value

USD 594.61M

P/E ratio (trailing)

-14.45

P/E ratio (forward)

-19.72

EPS (trailing)

-1.31

EPS (forward)

-0.96

PEG ratio

n/a

Price to book

55.68

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

12.29

Employees

16

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Nuvectis Pharma, Inc. and compare it with other stocks.